	Application Number	09/293,670
	Confirmation Number	5176
DECLARATION OF JOSEPH FISHER UNDER	Filing Date	April 16, 1999
37 C.F.R. §1.131	First Named Inventor	Joseph Fisher
	Examiner	Teresa Wessendorf
	Group Art	1639
	Attorney Docket No.	RIGL-036CIP

This Declaration with the attached Exhibits are being submitted in conjunction with the Applicants' Response to the Office Action dated February 24, 2006.

- I, Joseph Fisher, M.D. Ph.D. do hereby declare as follows.
- 1. I am listed as an inventor of the above-referenced patent application.
- 2. Between June and September, 1997, I was a Scientist at Rigel Pharmaceuticals, Inc. (hereinafter "Rigel"). During this time, I was part of a program focused on the discovery of intracellularly-active peptides. The strategy employed by this program involved infecting cells with a library of retroviral vectors encoding candidate peptides, and selecting cells with an altered phenotype using fluorescence activated cell sorting (FACS)-based methods. The idea of using more than five FACS parameters to identify retrovirally-delivered, intracellularly-active peptides was developed before July 31, 1997.
- 3. I understand that the claimed subject matter of the above-referenced patent application relates to screening methods that include sorting a population of retrovirally infected cells using at least five fluorescence activated cell sorting (FACS) parameters. I

have been asked to provide factual evidence relating to my activities at Rigel with respect to the claimed subject matter before and after July 31, 1997.

- 4. Experiments confirming the applicability of FACS-based screening methods that employ at least five FACS parameters to the discovery of retrovirally-delivered intracellularly-active bioactive peptides were performed prior to July 31, 1997.
- 5. Exhibit A, which is a copy of pages 24 and 25 of my laboratory notebook, describes the results of an experiment in which cells were treated to induce exocytosis, and sorted using five FACS parameters. Exhibit A is dated prior to July 31, 1997. The top four graphs of page 25 show FACS results obtained from DMSO-treated cells (control), and the bottom four graphs of page 25 show FACS results obtained from A23187-treated cells (experimental). The top left graph of each group of four graphs shows results obtained from the parameter used to detect FM143, a fluorescent dye. The top right graph of each group of four graphs shows results obtained from the parameter used to detect FITC, another fluorescent dye. The bottom left graph shows results obtained from the parameter used to detect propidium iodide. The bottom right graph shows results obtained from parameter used to detect front light scatter as well as, independently, the parameter used to detect side light scatter. Thus, Exhibit A demonstrates the applicability of FACS methods that employ at least five FACS parameters to the discovery of retrovirally-delivered intracellularly-active bioactive peptides, before July 31, 1997.
- 6. Exhibit B, which is a copy of pages 112 to 120 of my laboratory notebook, describes an experiment in which and MC9 and CEM cells are transfected with a library of retroviral vectors that encode peptides. Exhibit B demonstrates that CEM and MC9 cells were transfected with a library of retroviral vectors between August 22 and August 27, 1997.

7. In September 1997, a method that included infecting cells with a library of retroviral vectors encoding candidate bioactive peptides, and selecting cells with an altered phenotype using five fluorescence FACS parameters was reduced to practice.

8. Exhibit C, which is a copy of pages 138 and 139 my laboratory notebook, describes an experiment in which retroviral vector library-infected cells are stimulated staurosporine to induce apoptosis, and sorted using five FACS parameters: side scatter ("ssc"), front light scatter ("fsc"), and three separate fluorescence parameters: ("fl1", "fl2" and "fl3"). Results for control cells not contacted with staurosporine are shown in the graphs on the left hand side of page 139, and results for experimental staurosporine-treated cells are shown in the graphs of the right hand side of page 139. Thus, Exhibit C demonstrates reduction to practice of a method that includes infecting cells with a library of retroviral vectors encoding candidate bioactive peptides, and selecting cells with an altered phenotype using five FACS parameters, on September 8, 1997.

9. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: June 25, 2006

oseph Fisher, M.D. Ph.D.,

Attachments: Exhibits A - C

771	7~?	,
11	11	946

m Page No._

8/22/97

EXHIBITB

Phoenix E Cell Transfections of For MC9 cell Infections

- Use Susans Protocol (xZ) So Z hells of 6 hell Plate / Transfection

- ONA- From Jerny Wary 1 (10Mg) = 6.6) Rab3a and Synaptotagram

2 6.3) Constructs

3 8.9) Rorall's Numericate

4 9.1) Constructs

4 9.1) Constructs

5 - New IRES Hook 43-13 129.13 10Mg = 11.6)

From

6 - " " 6FP 610.25 010-25 10Mg • 11.1)

- Follow Siscus Protocol- Put Preciptale / Chargine on cells at 11AM - Mice Pepper & Preciptale Scien on all Transfectats

Protocol on mext Page.

- Most 1x is Property Medic - Add 2ml/vell Fresh Medic

tei fragger id.

			Book No.		<u>.</u>		1
Page No							
Protocol for transfection of Ph	ioenix cells	and inf	ection o	f nona	dheren	t targe	et cells
		•	-				
Day 1: seed Phoenix cells (Es or As) in 6 well plat	tes at 8x10 ⁵ cells	in 1.5 ml (DMEM +	10% FBS	+ P/S) pe	r well	
Day 2: CaPO ₄ Transfection		*	Zueils		. •		
per well:	5ug DNA 30.5ul 2M C 219ul H₂O 250ul 2X HB	. •	4	049 DNA 512 2MC 1382 Hz 1002 2X	aclz D		
allow all reagents to come to room tempera	iture 30mins. bef	ore startin				1)	
add 50mM chloroquine at 2ul/well (50um fi	inal)						
pipet 5ug DNA to side of tube pipet 30.5ul of 2M CaCL ₂ away from the D mix the two together with the addition of 21 then using a 1ml pipet, add 250ul of 2X H HBS batch dependent) immediately add mixture dropwise to well microscopically visible precipitate should ap	19ul of miliQ H ₂ BS and quickly l	bubble air	-	e pipet fo	r 2 to 10 s	ecs. (the	time is 2
incubate 8hrs remove medium, wash once, and replace w	rith 1.5ml mediu	m	•				
Dāý3:							
move transfected plates to 32°C							
Day 4: Infection of target cells collect virus supernatent from transfected wor 1.5ul 5mg/ml protamine sulfate cfg out cells and debris at 2500 RPM for 5 count target cells and distribute 5x10 ⁵ cells resuspend each pellet of target cells with virus seal plate with parafilm and cfg at RT for 90 Remove parafilm and incubate plate over ni	wells (1.5 ml) into mins. or alternat per virus supe to rus supe and tran 0 mins. at 2500 I	ively, filte 15ml tube isfer to one	r through .es and pelle	45um acre et 5 mins.	odisc syrir 2500 RPN	nge filter	
Day 5: collect and pellet each well of target cells an	nd resuspend in 4	ml and tra	nsfer each	to a 6cm j	plate		
Day 7 or Day 8: at 48 to 72 hrs. post infection target cells ar	e ready to analy:	ze for expr	ession				
 					 	···	
					la.	To Pag	je No
Sed a Understood by me, Date	Invented b	last!	182		Date 8/22/9	,	
amegrene Mela	Recorded	by			0/24/		

m Page No.__ | 8/23/97 |

- Transfections of \$E Cells (Cont.)

- This morning. 24 hrs post Transfeotini Start Lock at Cells by Fluciousene.

6FP @ Cells Scen in #3, 4, and 6 3 and 4 must be CTIG Vector (induable with Ires GFP) 1 and 2 " be just Hook vector.

- Remoe old Media

- Add 2ml/ well of Warmed MC9 Media - 12AM

MC9 Paste Control Pophicles

Mc9 alls - WT

Socked Hook > ~75% Hook 1 From Amy.

Synaptotymn -50%"

RAB - "

- Asprale 2ml Cells, Take upin .3ml MT 100) /Tule

=> one gets FM 143 /MM | 370c => 30'

VIALIN FACSCAN

-001 WT -2 Hook -3 Synaptotegra - 4 RAB 5 - WT 6 + WT 7 8 + HOUK 9 - HOUK 9 - Symptotagn. 10 - RAB 17

To Page No.__


tnessed & Understood by me,


Date Nolas


Invented by TM

Date

01-5/91







Project No			'
Book No	TITLE		
18/2477)		i	
Mc9 Infectors (Cont.)	A Yesterday		
- ~ 11 An, Tale Glis out of - Tale up Pellets 1 > 6 win	Hells/ Pool, Wast	- tells int cont nc; reduction Plateria	T-755
7) Quick Look at #6 Shared	Some GFP @ Co	٠. يا	kan para kanasan kanasan kereseri
Lives GFP Library Inf. Transfeeds	<u>~</u>	مسلم بر بر بر بر	a contract to a second contract of the second
-Susan Plated 20 60 - Randy Sypphed DUA 10- - For Each 60mm Plate of	mm Plates of 9 62 Library - 14 me add (Plates have	BE Cells Yesterdy A , ires GFP 850 Aug li Gml of Media)	odg ~ 40% Conflict
/d /7 8	82 Chlorogure, 150m Ong ONA (11.8 222 CaUZ 1762 Hzo ml 20 HBS	Ti4sfeck	od 17 Plates Fram -> ~12:30 AM
	ila Standard Praedu	K.	
~ 6:30PM - Aspvate Media: - Wash Cells IX in PBS + Ca - Add Warm Mc9 Media: - >> 37°C ~ 7PM	ith plate 8 ml/Elask		
			To Page No.
		1	1 I

litnessed & Understood by me.

Whatas

Invented by

Date

8/11/00

tnessed & Understood by me,

American

Date
Invented by

Recorded by

To Page No.

Date

8/26/97

		the state of the s		
	Project No		Service Control of the Control of th	
	Book No	TITLE		
No	M-Lbray Infected-	Apoptois Induction	EXHBIT	C
XX Tal	(gae me Libray le 8ml (2x107 Cells) - 37°C 10AM -> \$PM Annexii PE Stan a	Infected Cells to to 4 4m1 Frost Media, 1 1 (6 Hars) 5 USUAL Procedul = Fil	st and Resure Metho Bry to Inn Stavespo	son pe only selling selling stars 743
	0		1 1	
	Sml of Cultie- Ad FACSCAN001 - L .002 Tr			
7 4bry - 0	GPP Bhnoted			
- Sphit	Back to ~ 106 /m	nl For Tomornis	~ 2.8 x 106 lm x 100 r Sort (x107/vial) at -8	_
	•			
, _				

To Page No...


itnessed & Understood by me

m Page No.__

Date Whofas

Invented by

Date 9/8/77



american by Recorded by Recorded by